| Product NDC: | 0173-0953 |
| Proprietary Name: | ZOVIRAX |
| Non Proprietary Name: | acyclovir |
| Active Ingredient(s): | 200 mg/5mL & nbsp; acyclovir |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SUSPENSION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0173-0953 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA019909 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19900402 |
| Package NDC: | 0173-0953-96 |
| Package Description: | 473 mL in 1 BOTTLE (0173-0953-96) |
| NDC Code | 0173-0953-96 |
| Proprietary Name | ZOVIRAX |
| Package Description | 473 mL in 1 BOTTLE (0173-0953-96) |
| Product NDC | 0173-0953 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | acyclovir |
| Dosage Form Name | SUSPENSION |
| Route Name | ORAL |
| Start Marketing Date | 19900402 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | ACYCLOVIR |
| Strength Number | 200 |
| Strength Unit | mg/5mL |
| Pharmaceutical Classes | DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] |